H.C. Wainwright Reiterates Sell Rating and $0 Price Target on Sarepta Therapeutics (SRPT)

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Sell rating $0 price target on Sarepta Therapeutics (NASDAQ: SRPT).

The analyst commented: "Yesterday evening, Sarepta announced that the company will voluntarily and temporarily pause all shipments of ELEVIDYS in the U.S., effective as of close of business Tuesday, July 22, 2025. This follows Monday's update from Children’s Hospital Los Angeles that the center had halted ELEVIDYS use, citing the regulatory uncertainty and awaiting further direction from the FDA. Though Sarepta claims its pause in shipments was voluntary, we think the company moved preemptively—bracing for an inevitable FDA mandate to pull the drug. After all, this 'voluntary' pause starkly contradicts Sarepta’s refusal just days earlier to comply with the FDA’s initial withdrawal request. While the FDA often allows sponsors to voluntarily withdraw their product, likely in order to preserve public image, Sarepta’s prior refusal to comply with such a request was a notable departure from the norm. Since the request for voluntary action was likely a courtesy, we think Sarepta's decision to comply was a capitulation after recognizing that the fight with the FDA was not winnable and that the agency would have strong-armed Sarepta into removing ELEVIDYS with a formal demand. See our most recent note on Sarepta's decision to refuse the FDA's request to stop selling ELEVIDYS in the U.S., Zero Intrinsic Value After ELEVIDYS U.S. Market Removal; Lowering PT to $0. We continue to believe the FDA will ultimately totally pull ELEVIDYS from the market, as its questionable efficacy profile is now overshadowed by a far graver concern: real risk of death for DMD patients. We reiterate our Sell rating and our 12-month price target of $0 per share."

For an analyst ratings summary and ratings history on Sarepta Therapeutics click here. For more ratings news on Sarepta Therapeutics click here.

Shares of Sarepta Therapeutics closed at $13.32 yesterday.

You May Also Be Interested In

• Phillips 66, Marathon Merger Talks Collapsed - Semafor
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat